Prevalence and Genotype Analysis of High Risk-human Papillomavirus Infection in Busan Women

부산지역 여성의 고위험군 인유두종 바이러스 유병률과 유전자형 분석

  • Kang, Chang-Soo (Department of Pathology, Busan Medical Center) ;
  • Lee, Kyung Eun (Department of Clinical Laboratory Science, Catholic University of Pusan)
  • 강창수 (부산의료원 병리과) ;
  • 이경은 (부산가톨릭대학교 임상병리학과)
  • Received : 2019.10.12
  • Accepted : 2019.10.24
  • Published : 2019.11.30


The main cause of cervical cancer is the human papillomavirus (HPV), and HPV DNA has been reported in 99.7% of patients with cervical cancer. The worldwide prevalence is highest for the HPV 16 and 18 genotypes, but HPV 52 and 58 have the highest prevalence in Asian countries, including Korea. The purpose of this study was to obtain basic data for the prevention of cervical cancer by analyzing the prevalence of HPV and the genotypes of high risk-human papillomavirus (HR-HPV) infection in women in Busan, Korea. We analyzed 1,995 cases of HPV in women who visited a Busan obstetrics and gynecology hospital from January 2016 to December 2017. The prevalence of HPV among these women was 28.3% (565/1995), and the HR-HPV infection rate was 75.4% (426/565). The HR-HPV genotype with the highest prevalence was HPV-52 (63/565, 11.2%), followed by HPV-58 (56/565, 9.9%), HPV-53 (55/565, 9.7%), and HPV-16 (53/565, 9.4%). The HR-HPV infection rate of young women 18-39 years old was 60.3% (257/426), so this age group should undergo continuous monitoring. The cytological results revealed a high infection rate for HPV-16 in high grade squamous intraepithelial lesions (HSIL) and squamous cell carcinoma (SCC). However, further evaluation of more samples is needed to confirm the HR-HPV genotypes related to the development of cervical epithelial neoplasias.


  1. Bernard, H. U., Chan, S. Y., Manos, M. M., Ong, C. K., Villa, L. L., Delius, H., Peyton, C. L., Bauer, H. M. and Wheeler, C. M. 1994. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence and phylogenetic algorithms. J. Infect. Dis. 170, 1077-1085.
  2. Bosch, F. X., Burchell, A. N., Schiffman, M., Giuliano, A. R., de Sanjose, S., Bruni, L., Tortolero-Luna, G., Kjaer, S. K. and Munoz, N. 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in Cervical Neoplasia. Vaccine 10, 1-16.
  3. Castle, P. E. 2004. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J. Low. Genit Tract. Dis. 8, 224-230.
  4. Chan, K. S., Li, W. H., Chan, Y. M., Ma, W. L., Cheung, J. L. and Cheng, A. F. 1999. High prevalence of human papillomavirus type 58 in china women with cervical cancer and precancerous lesion. J. Med. Virol. 59, 232-238.<232::AID-JMV18>3.0.CO;2-7
  5. Clifford, G. M., Gallus, S., Herrero, R., Munoz, N., Snijders, P. J., Vaccarella, S., Anh, P. T., Ferreccio, C., Hieu, N. T., Matos, E., Molano, M., Rajkumar, R., Ronco, G., de Sanjose, S., Shin, H. R., Sukvirach, S., Thomas, J. O., Tunsakul, S., Meijer, C. J. and Franceschi, S. 2005. IARC HPV Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366, 991-998.
  6. Cubie, H.A. 2013. Diseases associated with human papillomavirus infection. Virology 445, 21-34.
  7. De Sanjose, S., Diaz, M., Castellsague, X., Clifford, G., Bruni, L., Munoz, N. and Bosch, F. X. 2007. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis. 7, 453-459.
  8. Herrero, R., Hildesheim, A., Bratti, C., Sherman, M. E., Hutchinson, M., Morales, J., Balmaceda, I., Greenberg, M. D., Alfaro, M., Burk, R. D., Wacholder, S., Plummer, M. and Schiffman, M. 2000. Population-based study of human papillomavirus infection and cervical neoplasia in Rural Costa Rica. J. Natl. Cancer inst. 92, 464-473.
  9. Ho, G. Y., Bierman, R., Beardsley, L., Chang, C. J. and Burk, R. D. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338, 423-428.
  10. Hwang, H. S., Park, M., Lee, S. Y., Kwon, K. H. and Pang, M. G. 2004. Distribution and prevalence of human papillomavirus genotypes in routine pap smear of 2,470 Korean women determined by DNA chip. Cancer Epidemiol. Biomarkers Prev. 13, 2153-2156.
  11. Jung, K. W., Won, Y. J., Kong, H. J., Lee, E. S. and The Community of Population-Based Regional Cancer Registries. 2018. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015. Cancer Res. Treat. 50, 303-316.
  12. Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Beckmann, A. M., DeRouen, T. A., Galloway, D. A., Vernon, D. and Kiviat, N. B. 1992. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med. 327, 1272-1278.
  13. Lee, D. S., Kim, S. H., Park, S. J., Kim, T. U., Jin, H. W., Park, K. H. and Lee, H. Y. 2011. Human papillomavirus prevalence in gangwon province using reverse blot hybridization assay. Kor. J. Pathol. 45, 348-353.
  14. Lee, J. K. 2006. HPV DNA test as a Diagnostic tool for cervical cancer. Obstet. Gynecol. Sci. 49, 261-275.
  15. Myers, E. R., McCrory, D. C., Nanda, K., Bastian, L. and Matchar, D. B. 2000. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am. J. Epidemiol. 151, 1158-1171.
  16. Malagon, T., Drolet, M., Boily, M. C., Franco, E. L., Jit, M., Brisson, J. and Brisson, M. 2012. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12, 781-789.
  17. Min, K. J., Kwon, S. H., Kim, S. H., Kim, H. J., Seong, S. J., Song, Y. J., Shin, J. W., Lee, K. H., Lim, M. C., Chung, H. H., Ju, W., Hong, J. H., Kim, J. W., Bae, D. S. and Lee, J. K. 2016. Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline. J. Gynecol. Oncol. 27, 1-14.
  18. Nah, E. H., Cho, S., Kim, S. Y. and Cho, H. I. 2017. Human papillomavirus genotype fistribution among 18,815 Women in 13 Korean cities and relationship with cervical cytology findings. Ann. Lab. Med. 37, 426-433.
  19. Ostor, A. G. 1993. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 12, 186-192.
  20. Ouh, Y. T., Min, K. J., Cho, H. W., Ki, M., Oh, J. K., Shin, S. Y., Hong, J. H. and Lee, J. K. 2018. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016. J. Gynecol. Oncol. 29, 1-10.
  21. Pinto, A. P. and Crum, C. P. 2000. Natural history of cervical neoplasia: defining progression and its consequence. Clin. Obstet. Gynecol. 43, 352-362.
  22. Richart, R. M. and Barron, B. A. 1969. A follow-up study of patients with cervical dysplasia. Am. J. Obstet. Gynecol. 105, 386-393.
  23. Soto-De, L. S., Camargo, M., Sanchez, R., Munoz, M., Perez-Prados, A., Purroy, A., Patarroyo, M. E. and Patarroyo, M. A. 2011. Disribution patterns of infection with multiple types of human papillomaviruses and their association with risk factors. PLoS One 6, e14705.
  24. Sasagawa, T., Basha, W., Yamazaki, H. and Inoue, M. 2001. High risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol. Biomarkers Prev. 10, 45-52.
  25. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J. and Munoz, N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19.<12::AID-PATH431>3.0.CO;2-F
  26. WHO. 2014. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly. Epidemiol. Rec. 89, 465-491.